Apostolos Stathopoulos

Apostolos Stathopoulos

Professor, MD, PhD

Visiting Scientist

Treatment for brain tumors includes surgery, radiation therapy, and chemotherapy. These therapies may be delivered alone or in combination. Glioblastoma multiforme (GBM) is the most common and most malignant of all gliomas with 75% of patients dying within 18 months of diagnosis since they cannot be cured by surgery, radiation therapy, chemotherapy, or any other available treatment modality. The use of allogeneic/syngeneic/and xenogeneic cell lines and lysates may lead to a reduction in tumor size and perhaps rejection thereby increasing survival. In the future, allogeneic cell lines may also be used as a vaccination from common cancers. The manipulation of the immune system may be a useful way to have the body itself contribute to the treatment and prevention of cancer. Our research focuses on increasing the efficiency of the immune system to recognise and reject the malignant cells. Dr. Stathopoulos and his research team are one of the first groups in the world to be preparing an allogeneic vaccine for GBM. For more info, please go to ERC (Epitopoietic Research Corporation; http://ercbelgium.com/main/).